Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiagabine in Recent-Onset Schizophrenia
NCT00179465Phase 3Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2003
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Tiagabine + Antipsychotic with Placebo + Antipsychotic (2 arms). Primary endpoints: Neurocognitive Functions-Working Memory at 6 months and Neurocognitive Functions-Executive Function at 6 months. Started Nov 2003; status: active, not recruiting.
02
Drugs
tiagabine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00179465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179465.